Thermo Fisher acquires drug trial software firm Clario for up to $9.4bn

In a major private equity buy out deal, life science giant Thermo Fisher Scientific will pay up to $9.4bn cash to acquire drug trial data software firm Clario.

Read more: Thermo Fisher acquires drug trial software firm Clario for up to $9.4bn